title: [New perspectives in the evolution of prognosis and treatment of chronic lymphocytic leukaemia].
abstract: Chronic lymphocytic leukaemia is a disease with a variable clinical course and prognosis. New prognostic factors like immunoglobulin gene mutational status, cytogenetic abnormalities, CD38 and ZAP70 expression of malignant cells have been described recently. Conventional and biological prognostic factors allow to identify patients with unfavorable prognosis at early stage. Purin analogues, fludarabine and fludarabine based combinations can achieve complete hematological remission in approximately one third of patients with chronic lymphocytic leukaemia. Chemoimmunotherapy (most experience is obtained by combination of fludarabine + cyclophosphamide + rituximab) can increase not only complete remission rate, but also induce molecular remission in some cases. Stem cell transplantation as well as early and effective chemotherapy are curative choices of treatment in patients with chronic lymphocytic leukaemia.
authors.affiliation: Debreceni Orvos- és Egészségtudományi Centrum, Altalános Orvostudományi Kar, II. Belgyógyászati Klinika, Hematológiai Tanszék.
authors.forename: Béla
authors.initials: B
authors.lastname: Telek
authors.forename: László
authors.initials: L
authors.lastname: Rejto
authors.forename: Attila
authors.initials: A
authors.lastname: Kiss
authors.forename: Leonóra
authors.initials: L
authors.lastname: Méhes
authors.forename: Péter
authors.initials: P
authors.lastname: Batár
authors.forename: Miklós
authors.initials: M
authors.lastname: Udvardy
mesh_terms: D036541:ADP-ribosyl Cyclase / Q000032:analysis; D051997:ADP-ribosyl Cyclase 1; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D003520:Cyclophosphamide / Q000008:administration & dosage; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis* / Q000378:metabolism / Q000628:therapy*; D008562:Membrane Glycoproteins; D009154:Mutation; D011237:Predictive Value of Tests; D011379:Prognosis; D011505:Protein-Tyrosine Kinases / Q000032:analysis; D012008:Recurrence; D012074:Remission Induction; D000069283:Rituximab; D033581:Stem Cell Transplantation; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D051746:ZAP-70 Protein-Tyrosine Kinase
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D015703:Antigens, CD; D014408:Biomarkers, Tumor; D008562:Membrane Glycoproteins; D000069283:Rituximab; D003520:Cyclophosphamide; D011505:Protein-Tyrosine Kinases; D051746:ZAP-70 Protein-Tyrosine Kinase; C497261:ZAP70 protein, human; D036541:ADP-ribosyl Cyclase; C498154:CD38 protein, human; D051997:ADP-ribosyl Cyclase 1; D014740:Vidarabine; C024352:fludarabine